research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
Search
for
Sort by
Research
180-210 / 1000+ results 
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Single-Cell Transcriptomics Reveals a Senescence-Associated IL-6/CCR6 Axis Driving Radiodermatitis
Blocking certain immune signals can reduce skin damage from radiation therapy.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Janus Kinase (JAK) Inhibitors in Treating Alopecia Areata (AA)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Hair Growth-Promoting Effects of Enz MoriL on Human Dermal Papilla Cells Through Modulation of the Wnt/β-Catenin and JAK-STAT Signaling Pathways
Enz_MoriL from mulberry leaves helps hair growth by affecting specific cell pathways.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research One of the Best Treatments for Alopecia Areata Remains Unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research Case Report: Alopecia Areata Universalis Successfully Treated with Baricitinib
Baricitinib successfully treated severe hair loss.
research Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research The Diagnosis and Treatment of Hair and Scalp Diseases
Hair loss requires customized treatments based on its various causes and types.
research Treatment Options for Alopecia
The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.
research Treatment of Severe Alopecia Areata with Oral Tofacitinib: A Case Series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research Alopecia Areata: Multifactorial Disease Involving Genetic, Environmental, and Autoimmune Factors
Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
research Ruxolitinib Found to Cause Eyelash Growth: A Case Report
Ruxolitinib treatment may cause eyelash growth.
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research Review Article: Dermatological Complications of Immunosuppressive and Anti-TNF Therapy in Inflammatory Bowel Disease
Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
research The Good and Bad News About New Drugs for Treating Alopecia Areata
JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.